Capricor Therapeutics (NASDAQ:CAPR) Upgraded at B. Riley Financial

B. Riley Financial upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a neutral rating to a buy rating in a report issued on Monday, MarketBeat Ratings reports. They currently have $21.00 price objective on the biotechnology company’s stock, up from their prior price objective of $5.00.

CAPR has been the topic of several other reports. JonesTrading lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. Alliance Global Partners cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective on the stock. in a report on Tuesday, July 28th. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Roth Capital cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research note on Monday, July 27th. Finally, LADENBURG THALM/SH SH cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $30.25.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $8.56 on Monday. The firm has a market cap of $497.68 million, a P/E ratio of -3.49 and a beta of 0.72. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The company’s 50-day moving average price is $10.23 and its two-hundred day moving average price is $22.77.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, equities analysts predict that Capricor Therapeutics will post -1.71 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 25,000 shares of company stock valued at $759,158. Company insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently made changes to their positions in CAPR. KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $44,000. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth $43,000. Allworth Financial LP grew its position in Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 3,264 shares in the last quarter. SG Americas Securities LLC bought a new position in Capricor Therapeutics in the first quarter valued at $193,000. Finally, Focused Wealth Management Inc acquired a new stake in Capricor Therapeutics in the 1st quarter valued at $203,000. 21.68% of the stock is owned by institutional investors.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: B. Riley Financial upgraded Capricor Therapeutics to Buy, while a separate report said the consensus price target increased to approximately $21.42. These analyst views provide a potential counterweight to the litigation-related selling pressure. Capricor Therapeutics Raised to Buy at B. Riley Financial Capricor Therapeutics Consensus Price Target Increased
• Neutral Sentiment: Multiple firms, including Rosen, Hagens Berman, Kaplan Fox, and others, reminded investors that September 28, 2026 is the deadline to seek lead-plaintiff status in the securities class action. These releases largely repeat existing information rather than announce a new company development. Rosen Law Firm Capricor Deadline Notice Kaplan Fox Capricor Class Action Notice
• Negative Sentiment: The class-action allegations claim Capricor may have misled investors about the progress of the deramiocel biologics license application and failed to disclose that the final statistical analysis plan for the HOPE-3 trial had not been agreed upon with the FDA. The complaints cite adverse FDA briefing documents and an unfavorable advisory committee vote, which allegedly triggered a severe prior share-price decline. The allegations have not been proven, but the litigation creates legal, reputational, and regulatory overhang for CAPR. Capricor Shareholder Alert Bleichmar Fonti Capricor Class Action Announcement

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.